Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312464 | 1.00 | PTPRA (0.50) | PTPRASMN1; SMN2KDM6BOR51E2CYP3A4 | |
| Water SCHEMBL2000818 | 0.98 | PTPRA (0.49) | PTPRASMN1; SMN2KDM6BOR51E2CYP3A4 | |
| Water SCHEMBL2000820 | 0.98 | PTPRA (0.49) | PTPRASMN1; SMN2KDM6BOR51E2CYP3A4 | |
| SCHEMBL7433498 | 0.85 | PTPRA (0.33) | PTPRACYP3A4SLC7A5 | |
| Imidazole SCHEMBL1241426 | 0.84 | PTPRA (0.41) | PTPRASMN1; SMN2 | |
| SCHEMBL16452409 | 0.84 | PTPRA (0.34) | PTPRA | |
| SCHEMBL8255199 | 0.84 | PTPRA (0.34) | PTPRA | |
| SCHEMBL3803098 | 0.84 | PTPRA (0.34) | PTPRA | |
| SCHEMBL14640012 | 0.81 | PTPRA (0.33) | PTPRA | |
| SCHEMBL13201637 | 0.81 | PTPRA (0.33) | PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109922835-B | DCHBS active ester of PEG compound and application thereof | 诺和诺德股份有限公司 | 2023-08-04 | — | — | CN | claimed |
| EP-3983382-A1 | NOVEL NON-CODING HETEROCYCLIC AMINO ACIDS (NCHAA) AND THEIR USE AS HERBICIDES | Fortephest Ltd. (IL) | 2022-04-20 | — | — | EP | claimed |
| CN-107108714-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-113939499-A | Novel non-coding heterocyclic amino acids (NCHAA) and their use as herbicides | 福提费斯特有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-10946074-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2021-03-16 | — | — | US | claimed |
| CN-112300435-A | Environment-friendly polyurethane foaming agent and preparation method thereof | 宋庆红 | 2021-02-02 | — | — | CN | claimed |
| US-10689429-B2 | Double-acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2020-06-23 | — | — | US | claimed |
| US-10392428-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2019-08-27 | — | — | US | claimed |
| EP-3129041-B1 | DOUBLE-ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2019-06-12 | — | — | EP | claimed |
| US-20190038721-A1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-02-07 | — | — | US | claimed |
| EP-0975806-B1 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | INVITROGEN CORP (US) | 2006-06-21 | — | — | EP | claimed |
| EP-0975806-A4 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | LIFE TECHNOLOGIES INC (US) | 2004-10-06 | — | — | EP | claimed |
| EP-0946744-B1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | IDM IMMUNO DESIGNED MOLECULES (FR) | 2004-08-18 | — | — | EP | claimed |
| US-6767724-B2 | REPLICATING NUCLEOTIDE SEQUENCES USING MOLONEY MURINE LEUKEMIA VIRUS POLYMERASE; FORENSICS; MEDICAL DIAGNOSIS | INVITROGEN CORPORATION | 2004-07-27 | — | — | US | claimed |
| US-20030113712-A1 | Replicating nucleotide sequences using moloney murine leukemia virus polymerase; forensics; medical diagnosis | Life Technologies Corporation | 2003-06-19 | — | — | US | claimed |
| US-6495350-B1 | AMPLIFICATION OF NUCLEIC ACID MOLECULES BY REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE, ONE OR MORE DNA POLYMERASES, AND ONE OR MORE SULFUR-CONTAINING MOLECULES | INVITROGEN CORPORATION | 2002-12-17 | — | — | US | claimed |
| EP-0975806-A1 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | Life Technologies, Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1998044161-A9 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | — | 1999-03-11 | — | — | WO | claimed |
| WO-1998044161-A1 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | LIFE TECHNOLOGIES, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038721-A1 | GLP-1 DERIVATIVES AND USES THEREOF | GLP1R, DPP8, DPP7 | PTPRA 2276/4885SMN1; SMN2 4259/4885KDM6B 1307/4885 |
| US-10392428-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, VIP | PTPRA 4271/4885SMN1; SMN2 2317/4885KDM6B 3629/4885 |
| US-10689429-B2 | Double-acylated GLP-1 compounds | GLP1R, GIPR, GPR119 | PTPRA 4536/4885SMN1; SMN2 2152/4885KDM6B 181/4885 |
| US-10946074-B2 | GLP-1 derivatives and uses thereof | GLP1R, DPP8, DPP7 | PTPRA 2276/4885SMN1; SMN2 4259/4885KDM6B 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.